Drug intelligence / Profile preview

broadly neutralizing anti-enterovirus monoclonal antibodies

Development stage
Unknown
Lead developer
Amsterdam UMC
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Broadly neutralizing anti-enterovirus monoclonal antibodies represent an investigational class of immunotherapies designed to target and neutralize multiple clinically relevant enterovirus serotypes. The Academisch Medisch Centrum planned an exploratory, non-therapeutic human donor study ('Isolation of broadly neutralizing anti-enterovirus antibodies from healthy adult donors') to collect blood from healthy adults, measure serum neutralizing antibody titers, and isolate B cells producing these broadly neutralizing antibodies. However, the registered study status was updated to 'will not start', and no specific clinical-stage monoclonal antibody candidate has been advanced under this program.

Other names
broadly neutralizing anti-enterovirus antibodies
02

Targets

VP2 (Infectious bursal disease virus VP2 protein)Enterovirus capsid protein

Beyond the preview

Go deeper on broadly neutralizing anti-enterovirus monoclonal antibodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on broadly neutralizing anti-enterovirus monoclonal antibodies.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call